Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD

被引：0
作者：
Monica Dzwonkowski [1 ]
Janak Bahirwani [2 ]
Samantha Rollins [1 ]
Alicia Muratore [3 ]
Vikram Christian [4 ]
Yecheskel Schneider [1 ]
机构：
[1] Department of Gastroenterology, St. Luke’s University Health Network, Bethlehem, PA
[2] Department of Gastroenterology, Kadlec Clinic, Richland, WA
[3] Division of Gastroenterology and Hepatology, UNC School of Medicine, Chapel Hill, NC
[4] Department of Pediatric Gastroenterology, M Health Fairview, Minneapolis, MN
来源：
Current Gastroenterology Reports | 2025年 / 27卷 / 1期
关键词：
Crohn’s Disease; Herbal Remedies; Inflammatory Bowel Disease; Ulcerative Colitis;
D O I：
10.1007/s11894-025-00960-0
中图分类号：
学科分类号：
摘要：
Purpose of Review: Inflammatory bowel disease (IBD) can cause significant psychological, physical, and economic burdens on patients and healthcare systems. Studies show over one-fifth of patients will seek nontraditional methods of treatment for managing their symptoms. Understanding the benefits - and potential harms - of these therapies is important to provide holistic and evidence-based care to our IBD patients. Recent Findings: In this review, we present several studied herbal therapies for the management of both Crohn’s disease and ulcerative colitis. These include cannabinoids, Tripterygium wilfordii, Chios mastic gum, Boswellia serrata, Indigo Naturalis, curcumin, resveratrol, and Zingiber officinale. While these herbal remedies have been shown to have anti-inflammatory effects and positive outcomes in IBD patients, larger scale studies are lacking and the use may be limited by bioavailability, lack of standardization of formulations, and adverse reactions. Summary: In reviewing the literature, we discuss the current data available including benefits, adverse reactions, and considerations for use surrounding several of the more common herbal remedies used for IBD. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.
引用
收藏
相关论文
共 58 条
  • [1] Alatab S., Sepanlou S.G., Ikuta K., Et al., The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017, Lancet Gastroenterol Hepatol, 5, 1, pp. 17-30, (2020)
  • [2] Langhorst J., Wulfert H., Lauche R., Et al., Systematic review of complementary and alternative Medicine treatments in Inflammatory Bowel diseases, J Crohns Colitis, 9, 1, pp. 86-106, (2015)
  • [3] Holleran G., Scaldaferri F., Gasbarrini A., Curro D., Herbal medicinal products for inflammatory bowel disease: a focus on those assessed in double-blind randomised controlled trials, Phytother Res, 34, 1, pp. 77-93, (2020)
  • [4] Doeve B.H., van de Meeberg M.M., van Schaik F.D.M., Fidder H.H., A systematic review with Meta-analysis of the efficacy of Cannabis and cannabinoids for Inflammatory Bowel Disease: what can we learn from Randomized and Nonrandomized studies?, J Clin Gastroenterol, 55, 9, pp. 798-809, (2021)
  • [5] DiPatrizio N.V., Endocannabinoids in the gut, Cannabis Cannabinoid Res, 1, 1, pp. 67-77, (2016)
  • [6] Lamb C.A., Kennedy N.A., Raine T., Et al., British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults, Gut, 68, pp. s1-s106, (2019)
  • [7] Sexton K.A., Walker J.R., Targownik L.E., Et al., The inflammatory bowel Disease Symptom Inventory: a patient-report scale for Research and clinical application, Inflamm Bowel Dis, 25, 8, pp. 1277-1290, (2019)
  • [8] DEA to Hold Hearing on the Rescheduling of Marijuana. Accessed, (2024)
  • [9] Velez-Santiago A., Alvarez-Torres E., Martinez-Rodriguez R., Et al., A survey of Cannabis Use among patients with inflammatory bowel disease (IBD), Int J Environ Res Public Health, 20, 6, (2023)
  • [10] Lal S., Prasad N., Ryan M., Et al., Cannabis use amongst patients with inflammatory bowel disease, Eur J Gastroenterol Hepatol, 23, 10, pp. 891-896, (2011)
123456